AstraZeneca does not miss often, which is what makes the Wainua failure worth sitting with. The drug, developed with Ionis, is a gene silencer designed to knock down production of the transthyretin protein that builds up and stiffens the heart in ATTR cardiomyopathy. It flunked Phase 3.
That result matters beyond one company because it reopens a genuine scientific argument. The ATTR market is currently owned by stabilizers—drugs that lock the TTR protein into a stable shape rather than reducing how much of it gets made. Pfizer’s tafamidis built the category. BridgeBio’s Attruby has been taking share and just posted data showing it preserves kidney function in a way Jefferies called distinct from others in the space. The knockdown approach was supposed to be the next generation. Wainua’s failure suggests that either the mechanism is weaker than believed in the heart, or that stabilizers are simply harder to beat than the field assumed. For BridgeBio and Pfizer, this is very good news. For anyone building a TTR knockdown program, it is a real problem.
Meanwhile, the July 17 deadline is Friday. Hansoh’s GSK partnered ADC hit its overall survival endpoint in small cell lung cancer—more Chinese science delivering four days before Congress wants answers. The FDA approved Padcev plus Keytruda for muscle invasive bladder cancer, turning the ASCO data into a label. And med tech M&A quietly had its best first half since 2022.
Wainua Failed in ATTR Cardiomyopathy, and That Changes the Competitive Picture
What Happened: AstraZeneca and Ionis reported disappointing Phase 3 results for Wainua (eplontersen) in transthyretin mediated amyloid cardiomyopathy.
Two Strategies, One Disease, and the Wrong One Just Lost
ATTR cardiomyopathy is a progressive condition in which misfolded transthyretin protein accumulates in the heart, stiffening it and eventually causing heart failure. The disease has become one of the most commercially attractive cardiovascular markets in the industry because the patient population is larger than initially recognized and the diagnosis rate has improved dramatically with better screening.
Two fundamentally different strategies have been competing to treat it.
Stabilizers bind the TTR protein and hold it in its correct three dimensional shape so it does not misfold and deposit in the heart. Pfizer’s tafamidis pioneered this approach and built a multi billion dollar franchise. BridgeBio’s Attruby entered as the challenger, showed a survival signal versus tafamidis, and has been gaining commercial traction. The stabilizer class treats ATTR by preventing the protein from doing damage, even though the body keeps making the same amount of it.
Gene silencers take a completely different route. Instead of stabilizing the protein, drugs like Wainua use RNA targeting technology to reduce how much TTR the liver produces in the first place. Less protein made means less protein available to misfold and deposit in the heart. On paper, it is the more elegant approach—address the root cause rather than manage the downstream consequence. The field widely expected knockdown to eventually displace stabilizers as the preferred treatment.
Wainua’s Phase 3 failure undercuts that expectation. The drug did not deliver the cardiac benefit it needed to. That does not prove knockdown cannot work in the heart—other mechanisms, other drugs, and other trial designs might succeed where Wainua failed. But it does mean the theory that simply reducing TTR protein production automatically translates into better cardiac outcomes is no longer assumed. The biology turned out to be more complicated than the elegant hypothesis suggested.
Who Benefits and Who Is Hurt
BridgeBio and Pfizer are the clear beneficiaries. Their stabilizer drugs just had a major competitive threat weakened. Attruby’s growth trajectory looks safer than it did last week. The $1 billion preferred equity raise BridgeBio closed with Sixth Street and KKR in late June is now underwritten by a competitive landscape that just got friendlier. For Pfizer, tafamidis faces less pressure from the next generation of ATTR drugs, at least in the near term.
AstraZeneca and Ionis absorb a rare clinical miss. AstraZeneca has been on an extraordinary run—Enhertu expanding across indications, Truqap approved in PTEN prostate cancer, Baxfendy launched in hypertension, the Nuvalent deal running through GSK. A Phase 3 failure in a high value cardiovascular indication does not derail the company, but it removes what would have been a significant revenue opportunity and raises questions about the partnership’s future direction.
Every company running a TTR knockdown program now has to answer a harder question: why will their drug succeed where Wainua failed? The conversation with regulators, investors, and potential partners just became significantly more difficult. Some of these programs may quietly shift their focus from cardiomyopathy to polyneuropathy, where the knockdown approach has shown clearer benefit, rather than compete against stabilizers in a cardiac indication where the Phase 3 evidence now favors the incumbents.
Our Pro brief analyzes what the Wainua failure means for the knockdown versus stabilizer debate, assesses how BridgeBio and Pfizer’s competitive positions change, and identifies which TTR knockdown programs face the most strategic pressure. [Details below.]
Chinese Science Keeps Delivering, Four Days Before Congress Wants Answers
What Happened: Hansoh Pharma said its GSK partnered ADC, risvutatug rezetecan, met its primary endpoint of overall survival in a pivotal Phase 3 trial in small cell lung cancer.
An OS Win in the Hardest Lung Cancer
Small cell lung cancer is one of the most aggressive and treatment resistant cancers in oncology. It typically responds initially to platinum based chemotherapy but relapses quickly, and the options after first line are limited. An overall survival win in a pivotal trial against this disease is meaningful clinical data, and Fierce Biotech noted that Hansoh’s ADCs “continue to justify GSK’s decision to make them priority programs.”
The Timing Sharpens the China Story
This data point lands four days before the July 17 deadline for Merck, AbbVie, Lilly, Pfizer, and BMS to respond to the House Select Committee on China about their clinical trials there. Every week that Chinese assets keep reading out positive, the industry’s case for staying engaged gets stronger. The Hansoh/GSK ADC is exactly the kind of asset that makes pharmaceutical companies invest in Chinese science: a differentiated program producing registrational quality data in a disease with high unmet need.
But the same week brought a counterpoint. The FDA rejected the HLB and Hengrui liver cancer regimen for a third time, reportedly citing problems found during an inspection of a Chinese manufacturing facility. That is precisely the vulnerability critics point to. Chinese science delivers strong clinical data. Chinese manufacturing sometimes does not meet FDA standards. Both realities are true at once, and Friday is when the five named companies have to argue their side of it in writing.
The dual narrative captures the fundamental tension in the China pipeline story. The clinical value is real. The political and manufacturing risks are also real. The industry’s judgment call—that the clinical value outweighs the risks—is being tested in public for the first time this week. We will cover the July 17 responses on Friday.
The Bladder Cancer Data We Covered at ASCO Just Became a Label
What Happened: The FDA approved Padcev (enfortumab vedotin, Pfizer and Astellas) plus Keytruda (pembrolizumab, Merck) as neoadjuvant and adjuvant treatment for muscle invasive bladder cancer, regardless of whether patients are eligible for cisplatin chemotherapy.
From Conference Stage to Treatment Guideline
This is the EV 304 regimen we covered from ASCO, where it produced a 55.8% pathologic complete response rate versus 32.5% for chemotherapy. Moving an ADC plus checkpoint inhibitor combination into the perioperative setting—before and after surgery—expands the regimen into a much larger patient population than the metastatic setting where it started.
Bladder cancer treatment has been dominated by platinum based chemotherapy for decades. EV 304 showed that the combination of an ADC (Padcev, targeting Nectin 4) and a checkpoint inhibitor (Keytruda, targeting PD 1) can produce pathologic complete response rates that chemotherapy cannot match. A pCR of 55.8% means more than half of patients treated with the combination had no viable cancer cells remaining in their surgical specimen. That is a level of tumor eradication that redefines what is achievable before surgery.
The approval also eliminates the cisplatin eligibility requirement. Many bladder cancer patients are ineligible for cisplatin due to kidney function impairment, hearing loss, or other comorbidities. An ADC plus checkpoint inhibitor combination that works regardless of cisplatin eligibility gives physicians a universal perioperative option for the first time.
Padcev generated $1.94 billion in 2025 revenue and is now one of Pfizer’s top ten medicines. The perioperative expansion into a larger patient population should accelerate revenue growth. And China’s regulator accepted the filing for the same regimen, opening a second major market.
This is also part of the broader Pfizer/Seagen story we have tracked all year. Padcev is the crown jewel of Pfizer’s $43 billion Seagen acquisition. While other Seagen pipeline assets have struggled (sigvotatug vedotin missed Phase 3, Trillium assets culled), Padcev continues to deliver. The EV 304 perioperative approval strengthens the case that Padcev alone may justify the acquisition price, even as the pipeline beyond it narrows.
NICE Rejects Lumakras, Adding to the First Generation KRAS Pressure
The UK’s NICE issued final draft guidance rejecting routine NHS use of Amgen’s Lumakras in previously treated KRAS G12C lung cancer. The rejection comes in the same stretch that saw Genentech’s divarasib beat the approved standard in G12C lung cancer and BMS’s Krazati underperform chemotherapy in colorectal cancer. The first generation KRAS drugs are under pressure from every direction: clinically (next generation drugs performing better), commercially (modest sales relative to expectations), and now regulatorily (health technology assessments denying routine access).
The contrast with the RAS space more broadly could not be sharper. Revolution Medicines’ daraxonrasib was approved under CNPV in under 60 days. Genentech’s divarasib won head to head against the approved standard. And Lumakras cannot get routine NHS access. The value is migrating decisively from the first generation to the next.
Med Tech M&A Quietly Had Its Best First Half Since 2022
Med tech mergers and acquisitions reached $75.73 billion in the first half of 2026, the highest first half total since 2022 and well above every other year in BioWorld’s records. June alone contributed $12.21 billion, a sharp rebound from May’s quiet $1.51 billion.
The med tech deal wave has run alongside the biopharma boom without getting the same attention, but the drivers are similar: strong balance sheets, pressure to add growth in mature device categories, and a large field of scaled acquisition targets. The technology shifts underway—AI enabled diagnostics, surgical robotics, continuous monitoring, and the convergence of diagnostics with companion therapeutics—favor scale players who can absorb innovation faster than they can build it.
If you cover devices, diagnostics, or tools, the consolidation running through your sector is as intense as anything happening in drugs. The Merck KGaA/Bio Techne deal ($11.3 billion for life sciences tools) was the clearest crossover between the drug and tools sides, and it reflects the strategic logic driving both: the companies that supply essential infrastructure to the healthcare industry are strategically valuable and finite in number.
Strategic Themes
1. The ATTR Debate Just Tilted Decisively Toward Stabilizers
Wainua’s failure does not end the knockdown approach, but it removes the assumption that knockdown would inevitably displace stabilization. The stabilizer class—tafamidis and Attruby—just had its most significant competitive threat weakened. BridgeBio’s growth trajectory is safer. Pfizer’s tafamidis franchise faces less near term pressure. And every TTR knockdown program must now explain why it will succeed where Wainua failed. The field’s default assumption that reducing protein production would outperform stabilizing the protein has been challenged by the most definitive data available.
2. Friday Is the Real Test of Whether the China Probe Has Teeth
Hansoh’s ADC hit its OS endpoint in SCLC. The HLB/Hengrui liver cancer regimen was rejected for a third time over manufacturing issues. Chinese science delivers and Chinese manufacturing sometimes does not. Both realities will be on display when the five named companies submit their responses to the House Select Committee on Friday. The content of those responses—and more importantly, the committee’s reaction to them—will determine whether this probe is a political exercise that the industry navigates with carefully worded letters, or the beginning of a legislative process that adds meaningful friction to every future China deal.
3. Padcev Plus Keytruda Going Perioperative Is the ADC/IO Combination Model for Every Tumor
The EV 304 approval moves an ADC plus checkpoint inhibitor combination into the perioperative setting in bladder cancer. That is the template other tumor types will follow. Enhertu in early breast cancer. sac TMT plus Keytruda in lung cancer. The model—combine an ADC’s targeted tumor killing with a checkpoint inhibitor’s immune activation, then move it earlier in the treatment algorithm where cure is the goal—is becoming the dominant strategy in solid tumor oncology. Every new ADC approval in the perioperative setting expands the total market for both modalities.
4. The Med Tech Boom Deserves More Attention Than It Is Getting
$75.73 billion in first half med tech M&A. The highest since 2022. Running alongside a biopharma deal wave that has captured all the headlines. The devices, diagnostics, and tools sectors are consolidating at the same pace and for the same reasons: strong balance sheets, growth pressure, and technology shifts that favor scale. The life sciences tools and diagnostics subsectors, in particular, are at the intersection of AI, companion diagnostics, and precision medicine—three trends that make these companies strategically essential to drug developers and therefore attractive to acquirers.
Frequently Asked Questions
What happened with Wainua?
AstraZeneca and Ionis reported a Phase 3 failure for Wainua (eplontersen) in ATTR cardiomyopathy. The gene silencer approach, which reduces TTR protein production, did not deliver the cardiac benefit needed. The failure benefits stabilizer drugs (BridgeBio’s Attruby and Pfizer’s tafamidis) and raises questions about the knockdown approach in the heart.
What is the Hansoh/GSK ADC?
Risvutatug rezetecan, which met its primary endpoint of overall survival in a pivotal Phase 3 trial in small cell lung cancer. A Chinese developed asset partnered with GSK, delivering registrational quality data four days before the House China probe deadline.
What was the Padcev approval?
Padcev plus Keytruda approved for neoadjuvant and adjuvant treatment of muscle invasive bladder cancer. Based on EV 304 data showing 55.8% pathologic complete response versus 32.5% for chemotherapy. Works regardless of cisplatin eligibility. Padcev generated $1.94B in 2025.
Why was the HLB/Hengrui liver cancer regimen rejected?
The FDA rejected it for a third time, reportedly over problems found during an inspection of a Chinese manufacturing facility. It illustrates the manufacturing quality vulnerability that critics point to when arguing against reliance on Chinese drug production.
How is med tech M&A doing?
$75.73 billion in the first half, the highest since 2022. June contributed $12.21B after a quiet May. The consolidation is driven by the same forces as biopharma M&A: strong balance sheets, growth pressure, and technology shifts favoring scale.
When is the China probe deadline?
Friday, July 17. Four days from today. Merck, AbbVie, Lilly, Pfizer, and BMS must submit their responses to the House Select Committee on China.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Wainua Settles It, For Now. We analyze the knockdown versus stabilizer debate in ATTR cardiomyopathy, assess how BridgeBio and Pfizer’s competitive positions improve, and identify which TTR knockdown programs face the most pressure to pivot or deprioritize the cardiac indication.
Friday Is the China Deadline. We lay out what we expect the five named companies to say, what would genuinely surprise us, and how to read the committee’s response for signals about whether the Biotech Investment National Security Act gains real momentum.
Med Tech’s Quiet Consolidation. We map where the med tech deal wave is heading next, which subsectors are most ripe for consolidation, and how AI enabled diagnostics and companion therapeutics are reshaping strategic interest across the sector.
Plus: Padcev perioperative franchise analysis, Lumakras NICE rejection and first generation KRAS pressure, HLB/Hengrui manufacturing rejection, Section 232 countdown (18 days), and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
